3%双氯芬酸钠凝胶治疗日光性角化病的meta分析  

Meta analysis of 3% Diclofenac in treatment of actinic kerotosia

作　　者：周自广[1] 宋云焕[2] 

机构地区：[1]郑州市第一人民医院皮肤科,郑州450000 [2]郑州市第一人民医院妇科

出　　处：《医药论坛杂志》2015年第7期24-26,共3页Journal of Medical Forum

摘　　要：目的评价外用3%双氯芬酸钠凝胶治疗日光性角化病(AK)的疗效及安全性。方法计算机检索Cochrane图书馆、MEDLINE,EMBASE,NGC,CBM,纳入所有3%双氯芬酸钠凝胶治疗AK的随机对照试验。由两名研究者独立提取资料并进行方法学质量评估。试验数据的统计分析采用Cochrane协作网提供的Rev Man 4.3软件进行。结果共纳入3篇随机对试验(RCT),包括335例患者,meta分析结果显示:疗程30天时3%双氯芬酸钠凝胶临床疗效不优于安慰剂,差异无统计学意义;疗程60天及90天时3%双氯芬酸钠凝胶的临床疗效优于安慰剂,差异有统计学意义。不良反应轻微,主要为局部皮肤反应,但多为轻中度,患者具有较好的耐受性,没有患者因不良反应退出治疗。结论 3%双氯芬酸钠凝胶治疗日光性角化病是安全有效的。Objective To assess the benefit and safety of 3% diclofenac gel in the treatment of Actinic keratosis. Methods The Cochrane library, MEDLINE,Ovid, EMBASE, NGC, CBM were searched,the randomized controlled trials （RCTs） about 3% diclofenac gel for the treatment of Actinic keratosis all over the world were included. Two authors independently reviewed the data and assessed the quality. The data were inputted and analyzed by RevMan 4. 3 software. Results Three RCT studies involving 335 patients met the inclusion criteria. Meta analysis showed that treatment in 60 days and 90 days with 3 % diclofenac gel was effective, while 30 days, treatment was not superior to placebo. Commonly reported adverse events were localized facial irritation, most of them were mild or moderate, most patients were able to tolerate. No patients withdrew from treatment because of adverse effects. Conclusion 3% dielofenae gel was effective and safe in the treatment of actinic keratosis.

关 键 词：日光性角化病 双氯芬酸钠凝胶 随机对照试验 META分析 

分 类 号：R758.1[医药卫生—皮肤病学与性病学]